Molecular structure of Candesartan, CAS Number: 139481-59-7
Candesartan (CAS 139481-59-7)
See product citations (6)
Alternate Names:
Celexetil
Application:
Candesartan is a selective angiotensin II receptor antagonist
CAS Number:
139481-59-7
Purity:
≥98%
Molecular Weight:
440.45
Molecular Formula:
C24H20N6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Candesartan is a compound often utilized in the field of cardiovascular research, where its mechanism of action as an angiotensin II receptor antagonist is of particular interest. Studies involving candesartan are primarily focused on understanding the regulation of blood pressure and the pathophysiology of hypertension. In research applications, candesartan is used to investigate the effects of blocking the angiotensin II type 1 (AT1) receptor on the cardiovascular system. Additionally, the compound is involved in the study of renal function and the progression of certain types of chronic kidney disease, as angiotensin II plays a critical role in renal hemodynamics. Candesartan has also been used in research models to explore its potential impact on cardiac hypertrophy and heart failure.
Candesartan (CAS 139481-59-7) References
- Clinical pharmacokinetics of candesartan. | Gleiter, CH. and Mörike, KE. 2002. Clin Pharmacokinet. 41: 7-17. PMID: 11825094
- Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. | Doggrell, SA. and ,. 2004. Expert Opin Pharmacother. 5: 687-90. PMID: 15013936
- Candesartan for the treatment of hypertension and heart failure. | Ostergren, J. 2004. Expert Opin Pharmacother. 5: 1589-97. PMID: 15212609
- Candesartan for the management of heart failure: more than an alternative. | McKelvie, RS. 2006. Expert Opin Pharmacother. 7: 1945-56. PMID: 17020420
- Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. | Palaniyappan, A., et al. 2009. Mol Cell Biochem. 321: 9-22. PMID: 18777087
- Candesartan and renal protection: more than blocking angiotensin type 1 receptor? | Macconi, D. and Remuzzi, G. 2008. Kidney Int. 74: 1112-4. PMID: 18854846
- Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists. | Kaur, N., et al. 2008. Bioorg Med Chem. 16: 10210-5. PMID: 19013821
- Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis. | Yoshikawa, M., et al. 2009. J Cardiovasc Pharmacol. 53: 179-86. PMID: 19188828
- A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. | Zhenfeng Zheng, ., et al. 2011. J Renin Angiotensin Aldosterone Syst. 12: 365-74. PMID: 21421652
- Candesartan treatment enhances liposome penetration and anti-tumor effect via depletion of tumor stroma and normalization of tumor vessel. | Cai, XJ., et al. 2021. Drug Deliv Transl Res. 11: 1186-1197. PMID: 32822012
- Candesartan-induced cholestatic hepatitis: a case report. | Hermida Pérez, B., et al. 2020. Rev Esp Enferm Dig. 112: 959-960. PMID: 33226250
- Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress. | Khedr, NF., et al. 2022. Toxicol Appl Pharmacol. 435: 115827. PMID: 34906534
- Candesartan Reduces Neuronal Apoptosis Caused by Ischemic Stroke via Regulating the FFAR1/ITGA4 Pathway. | Ding, Y., et al. 2022. Mediators Inflamm. 2022: 2356507. PMID: 36117589
- Candesartan cilexetil: a review of its preclinical pharmacology. | Nishikawa, K., et al. 1997. J Hum Hypertens. 11 Suppl 2: S9-17. PMID: 9330999
- Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. | Morsing, P. 1999. J Am Soc Nephrol. 10 Suppl 11: S248-54. PMID: 9892173
Inhibitor of:
AGTRAP, ANG IV, Angiotensin, AP1AR, AT1, AT1a, Dear, MAS1L, Myotrophin, Olfr669, Olfr67, Olfr670, Olfr671, Olfr672, Olfr675, Olfr676, Olfr677, Olfr678, Olfr679, Olfr68, Olfr681, Olfr683, Olfr684, Olfr685, Olfr686, Olfr688, Olfr689, Olfr69, Olfr690, Olfr770, Olfr771, Olr1432, Olr1479, Olr1499, Olr255, Olr420, Olr421, Olr808, Olr853, RENBP, V1RA5, V1RA6, V1RA9, V2R11, Vasculin, WNK1, and WNK3.Activator of:
AT1, AT1a, AT2, Dear, and Podocin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Candesartan, 10 mg | sc-217825 | 10 mg | $47.00 | |||
Candesartan, 100 mg | sc-217825B | 100 mg | $94.00 | |||
Candesartan, 1 g | sc-217825A | 1 g | $151.00 |